Logo image of OKYO

OKYO PHARMA LTD (OKYO) Stock Fundamental Analysis

NASDAQ:OKYO - Nasdaq - GG00BMFG5F62 - Common Stock - Currency: USD

1.84  +0.19 (+11.52%)

After market: 1.8 -0.04 (-2.17%)

Fundamental Rating

0

OKYO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of OKYO have multiple concerns. OKYO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OKYO has reported negative net income.
OKYO had a negative operating cash flow in the past year.
OKYO had negative earnings in each of the past 5 years.
In the past 5 years OKYO always reported negative operating cash flow.
OKYO Yearly Net Income VS EBIT VS OCF VS FCFOKYO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -594.77%, OKYO is doing worse than 97.15% of the companies in the same industry.
Industry RankSector Rank
ROA -594.77%
ROE N/A
ROIC N/A
ROA(3y)-489.46%
ROA(5y)-354.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OKYO Yearly ROA, ROE, ROICOKYO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

OKYO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OKYO Yearly Profit, Operating, Gross MarginsOKYO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for OKYO has been increased compared to 1 year ago.
The number of shares outstanding for OKYO has been increased compared to 5 years ago.
OKYO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OKYO Yearly Shares OutstandingOKYO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
OKYO Yearly Total Debt VS Total AssetsOKYO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

OKYO has an Altman-Z score of -89.14. This is a bad value and indicates that OKYO is not financially healthy and even has some risk of bankruptcy.
OKYO has a Altman-Z score of -89.14. This is amonst the worse of the industry: OKYO underperforms 97.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -89.14
ROIC/WACCN/A
WACCN/A
OKYO Yearly LT Debt VS Equity VS FCFOKYO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M -8M

2.3 Liquidity

OKYO has a Current Ratio of 0.28. This is a bad value and indicates that OKYO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.28, OKYO is not doing good in the industry: 95.37% of the companies in the same industry are doing better.
OKYO has a Quick Ratio of 0.28. This is a bad value and indicates that OKYO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of OKYO (0.28) is worse than 94.83% of its industry peers.
Industry RankSector Rank
Current Ratio 0.28
Quick Ratio 0.28
OKYO Yearly Current Assets VS Current LiabilitesOKYO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

OKYO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.84%.
EPS 1Y (TTM)3.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by 0.00% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2Y0%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OKYO Yearly EPS VS EstimatesOKYO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -0.05 -0.1 -0.15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OKYO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OKYO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OKYO Price Earnings VS Forward Price EarningsOKYO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OKYO Per share dataOKYO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OKYO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OKYO PHARMA LTD

NASDAQ:OKYO (5/22/2025, 4:30:02 PM)

After market: 1.8 -0.04 (-2.17%)

1.84

+0.19 (+11.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2024-07-30/amc
Earnings (Next)N/A N/A
Inst Owners3.03%
Inst Owner Change102.21%
Ins Owners27.61%
Ins Owner Change0%
Market Cap40.06M
Analysts82.86
Price Target7.14 (288.04%)
Short Float %1.16%
Short Ratio1.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)60%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0
BVpS-0.44
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -594.77%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-489.46%
ROA(5y)-354.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.28
Quick Ratio 0.28
Altman-Z -89.14
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.73%
EPS Next Y0%
EPS Next 2Y0%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.47%
OCF growth 3YN/A
OCF growth 5YN/A